ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,084.61
-0.26%
Dow Jones
42,840.26
1.18%
Gold vs US Dollar
2,623.175
0.00%
Brent Oil
72.72
0.00%
Bitcoin
99,131.89
1.40%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) News

IGC Pharma (IGC)

IGC Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:IGC
DateTimeSourceHeadlineSymbolCompany
25/11/202413:30Business WireIGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
12/11/202421:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
27/09/202420:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
27/09/202420:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/09/202412:00Business WireIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
04/09/202412:00Business WireIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
26/08/202423:00Business WireIGC Announces Results of its 2024 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
22/08/202413:00Business WireIGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
20/08/202412:00Business WireIGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistAMEX:IGCIGC Pharma Inc
14/08/202420:23Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:IGCIGC Pharma Inc
09/08/202401:30Business WireIGC Pharma Reports First Quarter Fiscal 2025 ResultsAMEX:IGCIGC Pharma Inc
07/08/202420:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
02/08/202418:38Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/07/202413:00Business WireIGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetAMEX:IGCIGC Pharma Inc
09/07/202418:17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:IGCIGC Pharma Inc
09/07/202413:10Business WirePreclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety ProfileAMEX:IGCIGC Pharma Inc
08/07/202420:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
25/06/202413:00Business WireIGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
24/06/202423:30Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2024AMEX:IGCIGC Pharma Inc
18/06/202413:00Business WireIGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsAMEX:IGCIGC Pharma Inc
10/06/202413:00Business WireIGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 TetrahydrocannabinolAMEX:IGCIGC Pharma Inc
28/05/202413:00Business WireIGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1AMEX:IGCIGC Pharma Inc
22/05/202401:20Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:IGCIGC Pharma Inc
21/05/202418:00Business WireIGC Pharma to Attend BIO International Convention 2024AMEX:IGCIGC Pharma Inc
14/05/202401:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
14/05/202401:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
16/04/202411:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202413:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202419:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202415:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Your Recent History

LSE
MARS
Marston's
LSE
GEX
Georgina Energy
LSE
BARC
Barclays
LSE
SYME
Supply@me Capital
LSE
AAZ
Anglo Asian Mining
LSE
VAST
Vast Resources
LSE
GBP
Global Petroleum
LSE
CARD
Card Factory
LSE
QBT
Quantum Blockchain Techn...
LSE
TAVI
Tavistock Investments
LSE
KOD
Kodal Minerals
LSE
RKH
Rockhopper Exploration
LSE
PRES
Pressure Technologies
LSE
OPG
Opg Power Ventures
LSE
SRSP
Sirius Petroleum
LSE
PXC
Phoenix Copper
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads